Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global solid-phase oligonucleotide synthesis market was valued at USD 439 million in 2024 and is projected to reach USD 1.378 billion by 2031, exhibiting a CAGR of 18.2% during the forecast period.
Solid-phase oligonucleotide synthesis refers to the automated chemical synthesis of oligonucleotides (short DNA or RNA sequences) on solid support materials such as controlled pore glass or polystyrene beads. This technology enables precise, base-by-base addition of nucleotides with high efficiency and is fundamental to numerous applications in molecular biology, diagnostics, and therapeutics.
The market is driven by increasing demand for synthetic genes and DNA/RNA libraries for synthetic biology applications, rising adoption of next-generation sequencing (NGS) and CRISPR technologies requiring custom oligonucleotides, and growing investment in personalized medicine and RNA-based therapeutics. The COVID-19 pandemic further accelerated demand for synthetic RNA and DNA components for vaccine and therapeutic development.
Key players in the market include GenScript, GeneArt (Thermo Fisher Scientific), DNA 2.0 (ATUM), OriGene, BBI Solutions, Genewiz, Eurofins Genomics, Gene Oracle, and SBS Genetech, among others. These companies are actively engaged in developing high-throughput synthesis platforms and expanding their production capacities to meet growing demand.
Rising Demand for Personalized Medicine
The global shift towards personalized medicine and precision therapeutics continues to drive demand for custom oligonucleotides. Pharmaceutical companies increasingly rely on synthetic DNA/RNA fragments for targeted therapies, gene editing applications, and diagnostic test development, creating sustained market growth.
Expansion of Genomics Research
Academic institutions and research organizations worldwide are scaling up their genomics and proteomics research programs, requiring substantial amounts of high-quality oligonucleotides. The CRISPR revolution alone has increased demand for custom guides by over 300% in the past three years.
The pharmaceutical industrys investment in mRNA therapeutics has created unprecedented demand for modified oligonucleotides, with production scaling to meet clinical trial requirements
Biotechnology companies are investing heavily in advanced manufacturing capabilities, with several major players announcing new production facilities specifically for oligonucleotide synthesis in 2024 and 2025.
MARKET CHALLENGES
High Production Costs and Complexity
The sophisticated nature of solid-phase oligonucleotide synthesis requires significant expertise and expensive equipment. Small to medium enterprises face barriers to entry due to the high capital investment required, with advanced synthesizers costing $500,000 to $2 million per unit. Quality control and purification processes add another 30-40% to production costs.
Other Challenges
Supply Chain Vulnerabilities
The market experienced significant supply chain disruptions during the pandemic, with key raw materials experiencing 200-400% price increases. Specialty phosphoramidites and other reagents remain vulnerable to supply chain disruptions, particularly those sourced from single geographic regions.
Regulatory Hurdles and Compliance Costs
Stringent regulatory requirements across different regions create significant compliance costs for manufacturers. The FDA and EMA requirements for therapeutic-grade oligonucleotides involve complex validation processes that can take 18-24 months and cost millions of dollars. This particularly affects smaller players who cannot easily absorb these costs.
Emerging Markets and Untapped Potential
Asia-Pacific markets are showing the fastest growth rates, with China's pharmaceutical sector investing heavily in oligonucleotide production capabilities. India's biotech sector is growing at 22% annually, with increasing demand for research-grade and therapeutic oligonucleotides. The market is expected to reach $12.8 billion by 2028, with therapeutic applications accounting for approximately 65% of demand.
Advanced manufacturing technologies, including AI-driven optimization and machine learning quality control, are creating opportunities for higher yields and reduced costs. Several startups are focusing on disrupting traditional manufacturing methods with novel approaches that could reduce costs by up to 60% within five years.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Primers remain the foundational pillar of the market, driven by their indispensable role in fundamental molecular biology techniques like PCR and DNA sequencing. Their consistent and high-volume demand creates a stable revenue stream. Meanwhile, Large-scale Synthesis Oligos represent the most dynamic growth segment, fueled by the expanding therapeutic applications of oligonucleotides, particularly antisense oligonucleotides and siRNA, which require industrial-scale manufacturing capabilities to meet clinical and commercial demands. |
| By Application |
|
Commercial applications are the dominant force, propelled by the biopharmaceutical and diagnostic industries' increasing reliance on oligonucleotides for drug development, genetic testing, and personalized medicine. This segment benefits from significant R&D investment and the transition of oligonucleotide-based therapies from research to commercialization. The Academic Research segment, while smaller in scale, serves as a critical innovation engine, continuously exploring new genetic functions and therapeutic targets that eventually fuel future commercial pipelines. |
| By End User |
|
Pharmaceutical & Biotech Companies constitute the largest and most influential end-user segment. Their demand is characterized by a need for high-purity, GMP-grade oligonucleotides for therapeutic development and clinical trials. The strategic outsourcing of synthesis to specialized CROs & CDMOs is a significant trend, as these partners offer advanced technological expertise and scalable production capacity, allowing drug developers to accelerate timelines and manage risks more effectively compared to maintaining in-house synthesis facilities. |
| By Synthesis Scale |
|
Commercial/Good Manufacturing Practice (GMP)-scale synthesis is the foremost growth driver, reflecting the market's maturation as oligonucleotide drugs advance through regulatory approval and into the market. This segment demands the highest levels of quality control, documentation, and consistency. The transition from Research-scale to GMP-scale represents a critical value chain, with specialized CDMOs playing a pivotal role in bridging the technical and regulatory gap to ensure a reliable supply of materials for clinical and commercial use. |
| By Application Focus |
|
Therapeutic Development is the primary application focus, commanding the highest strategic interest and investment. This is due to the high value and transformative potential of oligonucleotide-based drugs for treating genetic disorders, cancers, and infectious diseases. The stringent requirements for safety and efficacy in this segment drive innovation in synthesis purity and modification chemistry. Diagnostics & Screening represents a steady, high-volume segment, essential for applications like genetic testing and pathogen detection, which rely on the specific binding properties of probes and primers. |
An Oligopoly of Established Giants and Specialized Niche Providers
The global solid-phase oligonucleotide synthesis market is characterized by a competitive landscape dominated by a handful of established biotechnology and life sciences companies that collectively hold a significant revenue share. In 2024, the global top five players commanded a substantial, though undisclosed, portion of the market's revenue. Leading players such as GenScript and GeneArt (Thermo Fisher Scientific) have solidified their positions through extensive product portfolios, robust R&D capabilities, and global distribution networks that serve both the commercial and academic research sectors. These companies heavily invest in advanced synthesis technologies and automation to cater to the growing demand for high-quality primers, probes, and large-scale synthesis oligos, driving innovation and setting industry standards. The market's high growth potential, projected at a CAGR of 18.2%, continues to attract strategic investments from these incumbents to maintain their dominance.
Beyond the top-tier leaders, the market includes a diverse array of other significant players that have carved out niches by specializing in specific applications, synthesis scales, or geographic markets. Companies like Eurofins Genomics and BBI (Biosearch Technologies) leverage their expertise in genomics services to offer reliable custom oligonucleotide synthesis. Smaller, specialized firms and regional players, such as SBS Genetech in Asia and Bio Basic, compete effectively by offering cost-competitive solutions, rapid turnaround times, and specialized products like linkers and adaptors. This competitive dynamic fosters a market environment with a range of options for customers, from large pharmaceutical companies requiring bulk-scale synthesis to academic laboratories needing smaller, research-grade oligos.
List of Key Solid-Phase Oligonucleotide Synthesis Companies ProfiledGenScript
Renesas Electronics Corporation
OriGene
BBI (Biosearch Technologies)
Eurofins Genomics
Gene Oracle
SBS Genetech
Integrated DNA Technologies (IDT)
LGC Biosearch Technologies
Sigma-Aldrich (Merck KGaA)
TriLink BioTechnologies
The global Solid-phase Oligonucleotide Synthesis market is exhibiting substantial expansion, with its value projected to surge from $439 million in 2024 to $1378 million by 2031, representing a compound annual growth rate (CAGR) of 18.2%. This vigorous growth is primarily driven by the escalating demand for oligonucleotides in therapeutic applications, including antisense oligonucleotides, siRNA, and aptamers, used in treating genetic disorders, cancers, and infectious diseases. Concurrently, the diagnostic sector continues to be a major consumer, utilizing synthesized oligonucleotides as primers and probes in PCR, next-generation sequencing, and various molecular diagnostic assays. The market's momentum underscores its critical role in advancing personalized medicine and precision diagnostics.
Other TrendsDominance of Primers Segment and Regional Market Dynamics
The primers product segment is a significant contributor to market revenue and is expected to maintain strong growth, reflecting its fundamental use in a vast majority of molecular biology techniques. From a geographical standpoint, North America, led by the United States, remains a dominant market due to its advanced biomedical research infrastructure and high concentration of pharmaceutical and biotechnology companies. However, the Asia-Pacific region, particularly China, is anticipated to witness the fastest growth rate. This expansion is fueled by increasing government and private investment in life sciences research, a growing biopharmaceutical industry, and the establishment of new manufacturing facilities by key global players.
Consolidated Competitive Landscape and Innovation FocusThe competitive environment features a mix of established giants and specialized suppliers, with the top five companies holding a significant combined market share. Leading players such as Genescript, GeneArt (Thermofischer), and Eurofins Genomics are focusing on strategic initiatives including mergers, acquisitions, and partnerships to expand their service portfolios and geographic reach. A key trend among competitors is the continuous investment in research and development to improve synthesis efficiency, scale, and purity, while also reducing production costs. The development of high-throughput and automated synthesis platforms is a critical area of innovation, catering to the growing demand for large-scale synthesis of oligonucleotides for therapeutic and diagnostic use.
Regional Analysis: Solid-phase Oligonucleotide Synthesis MarketEurope
Europe represents a highly significant and mature market for solid-phase oligonucleotide synthesis, characterized by a strong academic foundation and a growing pharmaceutical sector focused on personalized medicine. Countries like Germany, the UK, and France are major contributors, with extensive research activities in genomics and molecular diagnostics. The presence of leading CDMOs and a collaborative cross-border research environment under EU funding programs stimulates market growth. The region shows increasing adoption of oligonucleotides in therapeutic areas such as oncology and neurology, supported by a robust regulatory framework from the European Medicines Agency.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for solid-phase oligonucleotide synthesis, driven by rising investments in life sciences research, increasing government initiatives in biotechnology, and a growing pharmaceutical outsourcing industry. Countries like China, Japan, and South Korea are emerging as key hubs, with expanding capabilities in both research-grade and GMP-compliant synthesis. The large population base and rising prevalence of chronic diseases create a substantial long-term demand for diagnostic and therapeutic oligonucleotides. Cost-competitive manufacturing and a burgeoning contract research sector position the region for significant market expansion.
South America
The solid-phase oligonucleotide synthesis market in South America is in a developing stage, with growth primarily driven by academic research and increasing awareness of genetic therapies. Brazil and Argentina are the most active markets, with growing investments in biomedical research infrastructure. The market faces challenges related to funding and regulatory harmonization but shows potential for growth as regional capabilities in biotechnology expand and collaborations with international players increase.
Middle East & Africa
The Middle East & Africa region represents a smaller but emerging market, with growth focused on select countries possessing stronger healthcare and research infrastructures, such as Israel, South Africa, and a few Gulf Cooperation Council nations. Market development is largely tied to academic research, increasing diagnostic applications, and gradual investment in local biotechnology sectors. The region presents long-term growth potential as healthcare systems modernize and interest in precision medicine grows.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global solid-phase oligonucleotide synthesis market was valued at USD 439 million in 2024 and is expected to reach USD 1378 million by 2031.
Which key companies operate in Global Solid-phase Oligonucleotide Synthesis Market?
-> Key players include Genescript, GeneArt (Thermo Fisher Scientific), DNA 2.0 (ATUM), OriGene, BBI Solutions, Genewiz, Eurofins Genomics, Gene Oracle, and SBS Genetech, among others.
-> Key growth drivers include increasing demand for synthetic genes and DNA/RNA libraries, rising adoption of next-generation sequencing and CRISPR technologies, and growing investment in personalized medicine.
-> North America leads the market, while Asia-Pacific shows rapid growth potential.
-> Emerging trends include high-throughput synthesis platforms, automation in production, and expanding applications in RNA-based therapeutics.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates